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effects of vitamin D may play a role in ameliorating acute
GVHD pathogenesis. Vitamin D has been shown to suppress
Th1 and Th17 cytokine production, inhibit differentiation and
maturation of dendritic cells, promote Th2-cell development,
and increase expression of regulatory T-cells. We performed
a retrospective analysis to evaluate whether serumvitamin D
levels on day 30 after HSCT are predictive of organ-speciﬁc
GVHD.
Methods: Fifty-four patients undergoing allogeneic HSCT
at the University of Pennsylvania between January 2008
and December 2012 were included in the analysis.
Serum 25-hydroxyvitamin D (25OHD) concentrations were
determined on day 30 following HSCT. We analyzed pa-
tients in two groups according to their median day-30
25(OH)D concentration (<20 and 20 ng/mL). The asso-
ciations between vitamin D levels and other variables were
conducted using Pearson correlations and t-tests. We then
used a landmark analysis to estimate the impact of day 30
vitamin D levels on subsequent clinical outcomes. Univar-
iate analyses were performed using cumulative incidence
and Cox regression analyses. Multivariable models were
constructed using the backward elimination method. We
also conducted immunophenotyping of day-30 peripheral
blood samples on patients who had low vs. normal vitamin
D levels.
Results: The median 25(OH)D concentration on day 30 was
20 ng/mL (range 6 - 50), reﬂecting severe vitamin D deﬁ-
ciency in half of the patients. Vitamin D levels signiﬁcantly
correlated with age, disease type, need for TPN during
transplant and day-30 albumin levels. In multivariate anal-
ysis of outcomes, day-30 vitamin D levels inversely corre-
lated with risk of acute skin GVHD (HR 0.27; 0.07 e 1.01;
p¼0.05). This associationwas speciﬁc to patients undergoing
reduced-intensity conditioned (RIC) HSCT (p<0.001) and not
myeloablative HSCT (p¼0.44). Vitamin D deﬁcient patients
expressed > 4-fold higher levels of CCR4, a skin-homing
receptor, on peripheral blood T-cells as detected on ﬂow
cytometric analysis (p¼0.036). Day 30 vitamin D levels didnot signiﬁcantly impact the risk of gastrointestinal (HR 2.16;
0.76e 6.09; p¼0.15) or hepatic GVHD (HR 0.31; 0.078e 1.24;
p¼0.1). No differences were observed in overall acute grade
2-4 GVHD, chronic GVHD, OS or non-relapse mortality.
Conclusion: Vitamin D deﬁciency on day 30 after allogeneic
HSCT is associated with signiﬁcantly increased risk of grade
2-4 cutaneous acute GVHD and increased expression of CCR4
on peripheral blood T-cells in patients undergoing RIC HSCT.
Vitamin D may confer a protective effect against acute skin
GVHD via reduction in CCR4 expression.417
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The therapeutic potential of allogeneic stem cell trans-
plantation (allo-SCT) in patients with malignant diseases of
the hemato-lymphatic system is thought to depend apart
from conditioning with high dose therapy on the anti-tu-
mor effect provided by the immune system of the donor.
However, the immune system of the donor may exert severe
and difﬁcult to control graft-versus-host-disease (GvHD).
Efforts to dissect GvHD and graft versus-leukemia/lym-
phoma reactions (GvL) have remained dissatisfying. Here,
we report immune reactions observed after allo-SCT sug-
gesting that GvHD and GvL are related rather quantitatively
and correspond with achieving 100% donor chimerism
allowing the extinction of remaining host immune cells
regardless whether malignant or not. Clinical ﬁndings: A
patient wit relapsed T-PLL was treated with allo-SCT and
received stem cells from a matched unrelated donor (MUD).
After being in complete cytological and molecular remis-
sion she relapsed molecularly on day +351. The molecular
analysis revealed malignant cells at the level of 0.16% in the
blood. While alemtuzumab was used for bridging, on day
+383 a ﬁrst donor lymphocyte infusion (DLI) was applied.
Despite a second and third DLI application later, a steady
increase in the MRD level above 2x10-2 was noted. How-
ever, the fourth DLI application on could not be given
because the patient had developed acute GvHD of the skin.
At the same time MRD no longer was detectable by RQ-PCR
with a detection limit below 1x10-5. GvHD resolved upon
treatment and the patient is in continuous complete
remission for more than 5 years. Likewise, a quantitative
effect in the balance between donor and host immune cells
was observed when a patient received an ABO blood
group major incompatible graft from a MUD. Frequently,
in those situations a delayed recovery of the major in-
compatible erythropoiesis is observed due to persisting
isohemagglutinin producing donor cells. Here, even after
complete tapering of the immunosuppression and thera-
peutic approaches including rituximab anemia persisted.
After DLI application, the patient developed acute GvHD of
the skin but consecutively the anemia resolved. Conclusion:
In these informative situations DLI documented their efﬁ-
cacy in correcting a misbalanced immune system after
allo-SCT. While in the MRD situation remaining tumor
cells vanished with increasing doses of DLI exactly when
ﬁrst signs of GvHD occurred, in the ABO incompatible sce-
nario few remaining host immune cells producing iso-
hemagglutinins were eradicated with a small dose of DLI.
This leads to the conclusion that donor immunosurveillance
QOL Metric O-GVHD Estimate P NIH Eye score Estimate P
FACT-G No 0* 0.006 0 0* 0.05
ˇ
Yes -2.1 1 -0.7 0.40
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immune cells is malignant and that GvHD and GvL may be
more a quantitative than qualitative effect.2 or 3 -2.5 0.01
FACT-TOI No 0* <0.001 0 0* 0.03
ˇ
Yes -2.6 1 -1.5 0.04
2 or 3 -2.4 0.01
FACT-BMT No 0* 0.002 0 0* 0.08
ˇ
Yes -3.0 1 -1.3 0.19
2 or 3 -3 0.03
Lee Score** No 0* <0.001 0 0* 0.01
ˇ
Yes 2.8 1 1.7 0.01
2 or 3 2.1 0.02
ˇ
overall P value; *Estimate 0-reference category; **Lee symptom score-eye
component excluded418
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Background: Ocular GVHD (o-GVHD) is a known manifes-
tation of chronic GVHD (cGVHD). There are no prospective
studies of factors associated with o-GVHD or its impact on
quality of life (QOL). We analyzed the above endpoints using
the cGVHD consortium database; a prospective multi-center
longitudinal observational study.
Methods: The study included patients with cGVHD requiring
systemic treatment and enrolled within 3 months of diag-
nosis. O-GVHD was deﬁned as NIH eye score > 0 and patient
reported symptoms (> 1 on 0-10 eye related symptoms or
>20 on Lee symptom eye score). Variables associated with o-
GVHD at enrollment and subsequent new onset o-GVHD, and
the associations with QOL were studied.
Results: The cumulative incidence of o-GVHD at 2 y after
cGVHD diagnosis was 58%. Of the 290 patients with o-GVHD,
117 (40%) had it within 3 months of cGVHD diagnosis (“early
o-GVHD”). Chronic GVHD characteristics associated with
early o-GVHD included: more severe global cGVHD
(P<0.001), and greater severity of mouth (P¼0.001), esoph-
agus (P¼0.002), and liver (P<0.001) involvement. In a
multivariable analysis, female sex (OR 2.0, P¼0.01) and
higher prednisone dose at enrollment (P¼0.04) were asso-
ciated with o-GVHD. Early o-GVHD was not associated with
subsequent non-relapse mortality (HR 1.2, P¼0.53) or sur-
vival (HR 1.1, P¼0.85).
Late o-GVHD (new onset > 3 months after cGVHD diag-
nosis) occurred in 68 patients. The cumulative incidence of
late o-GVHD at 2-y post enrollment was 39%. Inmultivariable
modeling, presence of prior grade I-IV aGVHD (HR 1.8,
P¼0.03) was associated with shorter time to late o-GVHD,
while female donor into male recipient (HR 0.5, P¼0.05) was
associated with longer time to late o-GVHD onset.
The Table shows the association of o-GVHD with QOL
metrics, using all available visit data adjusted for center
effect, months since enrollment, platelet count, NIH
severity, bilirubin, prior aGVHD, and overlap vs. classic
cGVHD.
Conclusion: This large multicenter, prospective study shows
that o-GVHD affects 58% of patients at 2 y after a diagnosis of
cGVHD and is statistically associated with worse QOL and
more cGVHD symptoms compared to patients with cGVHD
without ocular involvement. Since o-GVHD may be due to
permanent destruction of lacrimal glands, prophylactic or
pre-emptive clinical trial strategies prior to onset ofirreversible dry eye syndrome are needed. Women, patients
on higher doses of prednisone, and those with a history of
acute GVHD seem to be at higher risk for o-GVHD.419
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Graft vs. host (GVH) effect mediated by donor T cells are
responsible for a signiﬁcant measure of therapeutic beneﬁt
as well as toxicity observed following stem cell trans-
plantation (SCT) between HLA-identical donors and re-
cipients. Donor T cell-mediated GVH effects may be
inﬂuenced by the aggregate alloreactivity to minor histo-
compatibility antigens (mHA) presented by the HLA in each
donor-recipient pair (DRP). The cumulative mHA variation in
each DRPmay thus be regarded as the alloreactivity potential
(AP) of that pair. To estimate AP in DRP, whole exome
sequencing (WES) of 4 matched-related (MRD) and 5 unre-
lated (URD) pairs was performed and revealed extensive
coding variation between them. To quantify the contribution
of exome sequence variation to AP, data from each DRP was
ﬁltered to isolate non-synonymous single nucleotide poly-
morphisms (SNP) in the GVH direction (polymorphisms
present in recipient and absent in donor). Logically, the SNP
involved in encoding peptides presented on the HLA in each
DRP will contribute to the AP in that pair. To identify these
peptides, the nucleotide sequence ﬂanking all of the several
thousand SNP in each DRP was obtained with the ANNOVAR
software package. All possible resulting nonameric-peptides
were interrogated in-silico for their likelihood to be pre-
sented by each of the 6 HLA class I molecules in individual
DRP, using the Immune-Epitope Database (IEDB) SMM al-
gorithm. The IEDB-SMM algorithm predicted between
1,043,514 and 366,426 peptides/DRP (w 18 peptides/SNP).
Peptide-HLA binding afﬁnity estimate was reported as an
IC50 value, which when <500 nM, predicts that peptides
